An emerging class of anticancer drugs called EZH2 inhibitors may greatly ... found that EZH2 inhibition combined with T-cell based immunotherapy worked better at shrinking non-Hodgkin B-cell ...

T cell-based immunotherapies ... Recent research has shed light on how EZH2 inhibitors, a class of anticancer drugs, can enhance these therapies' effectiveness, potentially transforming lymphoma ...

A new study shows how an anticancer drug triggers an "outside in" signal that gets it sucked into a cancer cell.